ANI Pharmaceuticals/$ANIP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
- Ticker
- $ANIP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 970
- Headquarters
- Baudette, United States
- Website
- www.anipharmaceuticals.com
ANIP Metrics
BasicAdvanced
$1.5B
15.86
$4.54
0.46
-
Price and volume
Market cap
$1.5B
Beta
0.46
52-week high
$95.57
52-week low
$69.58
Average daily volume
348K
Financial strength
Current ratio
2.91
Quick ratio
2.297
Long term debt to equity
1.013
Total debt to equity
1.048
Dividend payout ratio (TTM)
0.32%
Interest coverage (TTM)
4.00%
Profitability
EBITDA (TTM)
209.407
Gross margin (TTM)
60.40%
Net profit margin (TTM)
11.07%
Operating margin (TTM)
12.63%
Effective tax rate (TTM)
24.04%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
20.46%
Valuation
Price to earnings (TTM)
15.86
Price to revenue (TTM)
1.524
Price to book
2.58
Price to tangible book (TTM)
18.18
Price to free cash flow (TTM)
8.92
Free cash flow yield (TTM)
11.21%
Free cash flow per share (TTM)
8.072
Growth
Revenue change (TTM)
30.90%
Earnings per share change (TTM)
-725.55%
3-year revenue growth (CAGR)
34.58%
10-year revenue growth (CAGR)
26.96%
3-year earnings per share growth (CAGR)
115.22%
10-year earnings per share growth (CAGR)
18.22%
What the Analysts think about ANIP
Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.
Analyst projections of the future price of ANI Pharmaceuticals stock.
Bulls say / Bears say
ANI’s second-quarter revenue rose 25.9% year on year to $266.0 million, while adjusted EBITDA grew 32.4% to $71.6 million. It reaffirmed full-year revenue guidance of $1.08 billion to $1.14 billion and adjusted EBITDA guidance of $285 million to $300 million. (SEC)
Cortrophin Gel revenue grew 43.5% in the second quarter, and the new gout sales team reported broad early patient uptake. The expansion targets an estimated 285,000-patient market, giving the product another potential source of growth. (SEC)
ANI’s generics business grew 9.7% in the second quarter, helped by launches, and the company reported 12 new products launched year to date. FDA approval for generic everolimus tablets for oral suspension adds another product, in a reference market with reported annual US sales of about $123 million. (ANI Pharmaceuticals, StockTitan)
ANI lowered its 2026 Cortrophin Gel revenue outlook to $520 million–$540 million from $540 million–$575 million, despite strong year-on-year growth. That cut shows the company’s largest growth driver is not tracking its earlier expectations. (SEC)
ILUVIEN revenue fell 16.1% year on year to $18.7 million in the second quarter, even as Cortrophin lifted rare-disease sales. Continued weakness in this smaller branded product could blunt the benefit of Cortrophin’s growth. (SEC)
Second-quarter non-GAAP gross margin fell to 62.6% from 64.9% a year earlier, partly because of a higher mix of royalty-bearing products and the absence of prior-year prucalopride revenue. If this mix effect persists, faster sales growth may translate into less profit than investors expect. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
ANIP Financial Performance
Revenues and expenses
ANIP Earnings Performance
Company profitability
Upcoming events
No upcoming events
ANIP News
AllArticlesVideos
Funds containing ANIP
Fund name | Fund size | $ANIP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.11% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.08% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.